Mechanisms of the development of androgen independence in prostate cancer
- PMID: 15770516
- DOI: 10.1007/s00345-004-0473-1
Mechanisms of the development of androgen independence in prostate cancer
Abstract
The effectiveness of androgen ablation in the management of advanced prostate cancer is of limited duration, with the median length of response being only 18-24 months. The transition of the prostate cancer cell to an androgen independent phenotype is a complex process that involves selection and outgrowth of pre-existing clones of androgen-independent cells (clonal selection) as well as adaptive up-regulation of genes that help the cancer cells survive and grow after androgen ablation (adaptation). These two mechanisms share an important pre-requisite characteristic: prostate cancers are heterogeneous tumours comprised of various subpopulations of cells that respond differently to androgen withdrawal therapy. This tumour heterogeneity may reflect either a multifocal origin, adaptation to environmental stimuli, and/or genetic instability of the initial cancer. This review will reexamine the different mechanisms that enable prostate cancer cells to proliferate in an androgen depleted environment.
Similar articles
-
Transition to androgen-independence in prostate cancer.J Steroid Biochem Mol Biol. 2002 Jul;81(3):191-201. doi: 10.1016/s0960-0760(02)00064-x. J Steroid Biochem Mol Biol. 2002. PMID: 12163131 Review.
-
[Molecular genetic mechanisms of drug resistance in prostate cancer].Mol Biol (Mosk). 2015 Sep-Oct;49(5):716-27. doi: 10.7868/S0026898415050110. Mol Biol (Mosk). 2015. PMID: 26510590 Review. Russian.
-
Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence.Cancer Res. 2007 Oct 1;67(19):9001-5. doi: 10.1158/0008-5472.CAN-07-1072. Cancer Res. 2007. PMID: 17909000
-
Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.G Chir. 2010 Nov-Dec;31(11-12):568-74. G Chir. 2010. PMID: 21232206
-
Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.BJU Int. 2009 Aug;104(4):438-48. doi: 10.1111/j.1464-410X.2009.08695.x. Epub 2009 Jun 24. BJU Int. 2009. PMID: 19558559 Review.
Cited by
-
The vitamin D analogue BXL-628 inhibits growth factor-stimulated proliferation and invasion of DU145 prostate cancer cells.J Cancer Res Clin Oncol. 2006 Jun;132(6):408-16. doi: 10.1007/s00432-006-0086-8. Epub 2006 Feb 17. J Cancer Res Clin Oncol. 2006. PMID: 16485114 Free PMC article.
-
Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells.Br J Cancer. 2009 Nov 17;101(10):1731-9. doi: 10.1038/sj.bjc.6605358. Epub 2009 Oct 20. Br J Cancer. 2009. PMID: 19844233 Free PMC article.
-
CMTM5-v1 inhibits cell proliferation and migration by downregulating oncogenic EGFR signaling in prostate cancer cells.J Cancer. 2020 Apr 6;11(13):3762-3770. doi: 10.7150/jca.42314. eCollection 2020. J Cancer. 2020. PMID: 32328181 Free PMC article.
-
Identification of Potential Key Genes in Prostate Cancer with Gene Expression, Pivotal Pathways and Regulatory Networks Analysis Using Integrated Bioinformatics Methods.Genes (Basel). 2022 Apr 8;13(4):655. doi: 10.3390/genes13040655. Genes (Basel). 2022. PMID: 35456461 Free PMC article.
-
TRPV6 determines the effect of vitamin D3 on prostate cancer cell growth.PLoS One. 2011 Feb 11;6(2):e16856. doi: 10.1371/journal.pone.0016856. PLoS One. 2011. PMID: 21347289 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical